Human Embryonic Stem Cells: Progress in culture and maintenance
29 September 2008 | By
The pharmaceutical industry is at a crossroads: Research and Development costs continue to rise, whilst the pipeline of ‘blockbuster’ drugs is looking decidedly sparse for many of the major pharmaceutical companies. This state of affairs is compounded by the high attrition rates (>80%) of drug candidates, when they get to…